)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Repare Therapeutics (RPTX) investor relations material
Repare Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary8 Aug, 2025
Executive summary
Announced strategic re-prioritization, focusing on advancing Phase 1 programs RP-3467 (POLAR) and RP-1664 (LIONS), with a 75% workforce reduction by Q4 2025 and out-licensing of discovery platforms to DCx and lunresertib to Debiopharm.
Entered exclusive licensing agreement with Debiopharm for lunresertib, securing $10M upfront and up to $257M in milestones and royalties.
Out-licensed discovery platforms to DCx Biotherapeutics, receiving $1M upfront, $3M near-term, 9.99% equity, anti-dilution rights, and future milestones.
Net loss for Q2 2025 was $16.7M ($0.39/share), improved from $34.8M ($0.82/share) in Q2 2024, driven by lower R&D and G&A expenses and a $5.7M gain on sale of technology.
Actively evaluating strategic alternatives, partnerships, and sale opportunities to maximize shareholder value.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $109.5M as of June 30, 2025, expected to fund operations through 2027.
Q2 2025 revenue was $0.3M, down from $1.1M in Q2 2024, due to Roche agreement termination; six-month revenue was $0.3M versus $53.5M prior year.
Research and development expenses fell to $14.3M in Q2 2025 from $30.1M in Q2 2024, mainly due to workforce reductions and program terminations.
General and administrative expenses decreased to $6.0M in Q2 2025 from $8.3M in Q2 2024, reflecting lower personnel and IT costs.
Recognized a $5.7M gain from the DCx out-licensing transaction during the quarter.
Outlook and guidance
Cash runway expected through 2027, factoring in cost savings from restructuring and out-licensing deals.
Topline safety, tolerability, and early efficacy data from POLAR (RP-3467) and LIONS (RP-1664) Phase 1 trials anticipated in Q4 2025.
Ongoing strategic review to explore further partnerships and sale opportunities across the portfolio.
What is the financial impact of portfolio strategy?
What is the significance of LIONS and POLAR data?
What other strategic alternatives are being pursued?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Repare Therapeutics earnings date
Q3 20256 Nov, 2025
Next Repare Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Repare Therapeutics Inc. (RPTX) is a clinical-stage precision oncology company focused on the development of novel therapeutics using its synthetic lethality approach. The company leverages its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies aimed at genomic instability, including DNA damage repair.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage